Quia Pharma clarifies intention ahead of delisting
The company intends to raise new capital for a composition with creditors, resume collaboration with QUIA NZI and delist from Nasdaq First North.
See the latest news and media coverage for Quia Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Last updated
In short: Quia Pharma was delisted from Nasdaq First North and planned new capital for a creditor composition.
The company intends to raise new capital for a composition with creditors, resume collaboration with QUIA NZI and delist from Nasdaq First North.
Nasdaq decides on delisting due to missed payments and lack of business activity. The company agrees and cooperates for an orderly process. Focus is on GLP-1 patch as a private company.
The company transfers QuiaPEG Pharmaceuticals AB for 1 MSEK, reduces debt by 4 MSEK, takes a 3 MSEK loan and calls an extraordinary general meeting on 28 October 2025.
The company reported a negative operating result and low liquid funds, while a delay in the launch of health supplements is noted. The board is evaluating strategic alternatives.
As global markets grapple with economic uncertainty and inflation concerns, investors are increasingly looking towards Asia for opportunities, particularly in the realm of dividend stocks...
Stockholm, April 4, 2025- The Disciplinary Committee of Nasdaq Stockholm (the "Exchange") has found that QUIA PHARMA AB (publ) (the "Company") has breached the rules...
Track Quia Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.